Daily Stock Pick â€” February 14, 2026

ACXP â€“ Acurx Pharmaceuticals, Inc.

News: PipelineNews: Ibezapolstat is Phase 3â€“ready after positive Phase 2b (96% CC; 100% SCC) and successful FDA End-of-Phase 2 meeting; preparing international Phase 3. ([acurxpharma.com](https://www.acurxpharma.com/news-media/press-releases/detail/68/acurx-announces-positive-phase-2b-results-showing-100-of?utm_source=openai))

Score (0â€“1000): 640

ADVICE: Buy

Certainty: 62%

Forecast image URL: https://stockscan.io/stocks/ACXP/forecast

Verifier note: Best EV/lowest risk of set: late-stage, QIDP/Fast-Track antibiotic with supportive data and FDA-aligned Phase 3 plan; risks: micro-cap liquidity and likely dilution; avoid peers with wind-down/delisting or very low cash (e.g., TTOO winding down; BIAF cash tight). Sources: acurxpharma.com PRs; ACXP 10-Q (3/31/25); BIAF IR; PR on TTOO liquidation. ([acurxpharma.com](https://www.acurxpharma.com/news-media/press-releases/detail/80/acurx-announces-successful-fda-end-of-phase-2-meeting-and?utm_source=openai))

---
**Legend**
ğŸŸ¢ğŸŸ¢ğŸŸ¢ **Ultra Strong Buy** â€” Score > 800 â†’ â€œGuaranteed high returnâ€
ğŸŸ¢ **Strong Buy** â€” Score > 700 â†’ â€œAmazing Chancesâ€
ğŸŸ¡ **Buy** â€” Score â‰ˆ 600 â†’ â€œGreat Chancesâ€
ğŸ”´ **Ignore** â€” Score < 599 â†’ â€œIgnoreâ€

